β₃-Adrenoceptor ligand development history through patent review

Bibliography

• Perrone MG, Scilimati A. beta3-Adrenoceptor agonists and (antagonists as) inverse agonists: history, perspective, constitutive activity, and stereospecific binding. Methods Enzymol 2010;484:197-230
   PubMed Web of Science ®Google Scholar
• Arch JRS, Kaufmann AJ. beta3 and atypical beta-adrenoceptors. Med Res Rev 1993;21:663-729
   Google Scholar
• Moens AL, Yang R, Watts VL, Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system. J Mol Cell Cardiol 2010;48:1088-95
   PubMed Web of Science ®Google Scholar
• Boivin B, Lavoie C, Vaniotis G, Functional beta-adrenergic receptor signalling on nuclear membranes in adult rat and mouse ventricular cardiomyocytes. Cardiovasc Res 2006;71:69-78
   PubMed Web of Science ®Google Scholar
• Ghorbani M, Himms-Hagen J. Appearance of brown adipocytes in white adipose tissue during CL 316,243-induced reversal of obesity and diabetes in Zucker fa/fa rats. Int J Obes Relat Metab Disord 1997;21:465-75
   PubMed Web of Science ®Google Scholar
• Arch JRS. Perspectives from beta3-adrenoceptor agonists on pharmacology, physiology and obesity drug discovery. Naunyn Schmiedebergs Arch Pharmacol 2008;378:225-40
   PubMed Web of Science ®Google Scholar
• Barbe P, Millet L, Galitzky J, In situ assessment of the role of the beta1-, beta2- and beta3-adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue. Br J Pharmacol 1996;117:907-13
   PubMed Web of Science ®Google Scholar
• Rosenbaum M, Malbon CC, Hirsch J, Lack of beta3-adrenergic effect on lipolysis in human subcutaneous adipose tissue. J Clin Endocrinol Metab 1993;77:352-5
   PubMed Web of Science ®Google Scholar
• Ursino MG, Vasina V, Raschi E, The beta3-adrenoceptor as a therapeutic target: current perspectives. Pharmacol Res 2009;59:221-34
   PubMed Web of Science ®Google Scholar
• Geyer O, Bar-Ilan A, Nachman R, Beta 3-adrenergic relaxation of bovine iris sphincter. FEBS Lett 1998;429:356-8
   PubMed Web of Science ®Google Scholar
• Steinle JJ, Booz GW, Meininger CJ, Beta 3-adrenergic receptors regulate retinal endothelial cell migration and proliferation. J Biol Chem 2003;278:20681-6
   PubMed Web of Science ®Google Scholar
• Tagaya E, Tamaoki J, Takemura H, Atypical adrenoceptor-mediated relaxation of canine pulmonary artery through a cyclic adenosine monophosphate-dependent pathway. Lung 1999;177:321-32
   PubMed Web of Science ®Google Scholar
• Berlan M, Galitzky J, Bousquet-Melou A, Beta-3 adrenoceptor-mediated increase in cutaneous blood flow in the dog. JPET 1994;268:1444-51
   PubMed Web of Science ®Google Scholar
• Hom GJ, Forrest MJ, Bach TJ, Beta(3)-adrenoceptor agonist-induced increases in lipolysis, metabolic rate, facial flushing, and reflex tachycardia in anesthetized rhesus monkeys. JPET 2001;297:299-307
   PubMed Web of Science ®Google Scholar
• Trochu JN, Leblais V, Rautureau Y, Beta 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta. Br J Pharmacol 1999;128:69-76
   PubMed Web of Science ®Google Scholar
• Rautureau Y, Toumaniantz G, Serpillon S, Beta 3-adrenoceptor in rat aorta: molecular and biochemical characterization and signalling pathway. Br J Pharmacol 2002;137:153-61
   PubMed Web of Science ®Google Scholar
• Berlan M, Galitzky J, Montastruc JL. Beta3-adrenoceptors in the cardiovascular system. Fundam Clin Pharmacol 1995;9:234-9
   PubMed Web of Science ®Google Scholar
• Rozec B, Serpillon S, Toumaniantz G, Characterization of beta 3-adrenoceptors in human internal mammary artery and putative involvement in coronary artery bypass management. J Am Coll Cardiol 2005;46:351-9
   PubMed Web of Science ®Google Scholar
• Dessy C, Moniotte S, Ghisdal P, Endothelial beta 3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation 2004;110:948-54
   PubMed Web of Science ®Google Scholar
• Summers RJ, Papaioannou M, Harris S, Expression of beta 3-adrenoceptor mRNA in rat brain. Br J Pharmacol 1995;116:2547-8
   PubMed Web of Science ®Google Scholar
• Castillo-Melendez M, McKinley MJ, Summers RJ. Intracerebroventricular administration of the beta(3)-adrenoceptor agonist CL 316243 causes Fos immunoreactivity in discrete regions of rat hypothalamus. Neurosci Lett 2000;290:161-4
   PubMed Web of Science ®Google Scholar
• Lenard NR, Gettys TW, Dunn AJ. Activation of beta2- and beta 3-adrenergic receptors increases brain tryptophan. JPET 2003;305:653-9
   PubMed Web of Science ®Google Scholar
• Howe R. beta3-adrenergic agonists. Drugs Future 1993;18:529-49
   Google Scholar
• Simiand J, Keane PE, Guitard J, Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical beta-adrenoceptors. Eur J Pharmacol 1992;219:193-20
   PubMed Web of Science ®Google Scholar
• Glenmark Pharmaceuticals Ltd. Novel benzopyran compounds and process for their preparation and use. WO2003014113; 2003
   Google Scholar
• Berkowitz DE, Nardone NA, Smiley RM, Distribution of beta3-adrenoceptor mRNA in human tissues. Eur J Pharmacol Mol Pharmacol 1995;289:223-8
   PubMed Web of Science ®Google Scholar
• Pang Z, Wu N, Zhang X, GPR40 is partially required for insulin secretion following activation of beta3-adrenergic receptors. Mol Cell Endocrinol 2010;325:18-25
   PubMed Web of Science ®Google Scholar
• Strosberg AD. The beta3-adrenoreceptor.Volume 5. Taylor & Francis, New York; 2000. p. 84-5
   Google Scholar
• Houghten Pharmaceuticals. Use of a substituted 1,3-benzodioxole to reduce a wasting condition. US5597843; 1997
   Google Scholar
• Kim YS, Sainz RD. Beta-adrenergic agonists and hypertrophy of skeletal muscles. Life Sci 1992;50:397-407
   PubMed Web of Science ®Google Scholar
• Tisdale MJ. Pathogenesis of cancer cachexia. J Support Oncol 2003;1:159-68
   PubMedGoogle Scholar
• Candelore MR, Deng L, Tota L, Potent and selective human beta3-adrenergic receptor antagonists. JPET 1999;290:649-55
   PubMed Web of Science ®Google Scholar
• Perrone MG, Santandrea E, Bleve L, Stereospecific synthesis and bio-activity of novel beta3-adrenoceptor agonists and inverse agonists. Bioorg Med Chem 2008;16:2473-88
   PubMed Web of Science ®Google Scholar
• Univ. Degli Studi Di Bari. Beta-3 receptor ligands and their use in therapy. WO2008015558; 2008
   Google Scholar
• Fedorov VV, Lozinsky IT. Is the beta 3-adrenergic receptor a new target for treatment of post-infarct ventricular tachyarrhythmias and prevention of sudden cardiac death? Heart Rhythm 2008;5:298-9
   PubMed Web of Science ®Google Scholar
• Rozec B, Gauthier C. Beta 3-adrenoceptors in the cardiovascular system: putative roles in human pathologies. Pharmacol Ther 2006;111:652-73
   PubMed Web of Science ®Google Scholar
• Bungaard H, Liu C-C, Garcia A, beta3 adrenergic stimulation of the cardiac Na+-K+ pump by reversal of an inhibitory oxidative modification. Circulation 2010;122:2699-708
   PubMed Web of Science ®Google Scholar
• Rasmussen HH, Figtree GA, Krum H, Use of beta3-adrenergic receptor agonists in the treatment of heart failure. Curr Opin Investig Drugs 2009;10:955-62
   PubMedGoogle Scholar
• Gan RT, Li WM, Xiu CH, Chronic blocking of beta3-adrenoceptor ameliorates cardiac function in rat model of heart failure. Chin Med J (Eng) 2007;120:2250-5
   PubMed Web of Science ®Google Scholar
• Pott C, Brixius K, Bloch W, Beta3-adrenergic stimulation in the human heart: signal transduction, functional implications and therapeutic perspectives. Pharmazie 2006;61:255-60
   PubMed Web of Science ®Google Scholar
• Fujimura T, Tamura T, Tsutsumi T, Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle. J Urol 1999;161:680-5
   PubMed Web of Science ®Google Scholar
• Kissei Pharmaceutical. 2-Methylpropionic acid derivatives and medicinal compositions containing the same. EP1072583; 2001
   Google Scholar
• Otsuka A, Shinbo H, Matsumoto R, Expression and functional role of beta-adrenoceptors in the human urinary bladder. Naunyn Schmiedebergs Arch Pharmacol 2008;377:473-81
   PubMed Web of Science ®Google Scholar
• Takasu T, Ukai M, Sato S, Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. JPET 2007;321:642-7
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Chapple CR. beta3-Adrenoceptors in urinary bladder. Neurourol Urodyn 2007;26:752-6
   PubMed Web of Science ®Google Scholar
• Marcus JD. Emerging drugs for treatment of overactive bladder and detrusor overactivity. Expert Opin Emerg Drugs 2008;13:431-46
   PubMed Web of Science ®Google Scholar
• Michel MC, Ochodnicky P, Summers RJ. Tissue functions mediated by beta3-adrenoceptors – findings and challenges. Naunyn Schmiedebergs Arch Pharmacol 2010;382:103-8
   PubMed Web of Science ®Google Scholar
• Bianchetti A, Manara L. In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical beta-adrenoceptors in rat colon. Br J Pharmacol 1990;100:831-9
   PubMed Web of Science ®Google Scholar
• De Ponti F, Gibelli G, Croci T, Functional evidence of atypical beta3-adrenoceptors in the human colon using the beta 3-selective adrenoceptor antagonist, SR 59230A. Br J Pharmacol 1996;117:1374-6
   PubMed Web of Science ®Google Scholar
• De Ponti F, Cosentino M, Costa A, Inhibitory effects of SR 58611A on canine colonic motility: evidence for a role of beta3-adrenoceptors. Br J Pharmacol 1995;114:1447-53
   PubMed Web of Science ®Google Scholar
• Bharucha AE, Camilleri M, Zinsmeister AR, Adrenergic modulation of human colonic motor and sensory function. Am J Physiol 1997;273:997-1006
   PubMed Web of Science ®Google Scholar
• Cellek S, Thangiah R, Bassil AK, Demonstration of functional neuronal beta(3)-adrenoceptors within the enteric nervous system. Gastroenterology 2007;133:175-83
   PubMed Web of Science ®Google Scholar
• Kuratani K, Kodama H, Yamaguchi I. Enhancement of gastric mucosal blood flow by beta-3 adrenergic agonists prevents indomethacin-induced antral ulcer in the rat. JPET 1994;270:559-65
   PubMed Web of Science ®Google Scholar
• Sevak R, Paul A, Goswami S, Gastroprotective effect of beta3 adrenoreceptor agonists ZD 7114 and CGP 12177A in rats. Pharmacol Res 2002;46:351-6
   PubMed Web of Science ®Google Scholar
• Vasina V, Abu-gharbieh E, Barbara G, The beta3-adrenoceptor agonist SR58611A ameliorates experimental colitis in rats. Neurogastroenterol Motil 2008;20:1030-41
   PubMed Web of Science ®Google Scholar
• Schemann M, Hafsi N, Michel K, The beta3-adrenoceptor agonist GW427353 (solabegron) decreases excitability of human enteric neurons via release of somatostatin. Gastroenterology 2010;138:266-74
   PubMed Web of Science ®Google Scholar
• Yasuhiko I, Naoki A, Yukio H. Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder. Korean J Urol 2010;51:811-18
   PubMedGoogle Scholar
• Palm D, Lang K, Niggemann B, The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 2006;118:2744-9
   PubMed Web of Science ®Google Scholar
• Perrone MG, Notarnicola M, Caruso MG, Upregulation of beta3-adrenergic receptor mRNA in human colon cancer: a preliminary study. Oncology 2008;75:224-9
   PubMed Web of Science ®Google Scholar
• Bardou M, Rouget C, Breuiller-Fouche M, Is the beta3-adrenoceptor (ADRB3) a potential target for uterorelaxant drugs? BMC Pregnancy Childbirth 2007;7:S14
   PubMedGoogle Scholar
• Dennedy MC, Friel AM, Gardeil F, Beta-3 versus beta-2 adrenergic agonists and preterm labour: in vitro uterine relaxation effects. Br J Obstet Gynaecol 2001;108:605-9
   Google Scholar
• Rouget C, Bardou M, Breuiller-Fouche M, beta3-Adrenoceptor is the predominant beta-adrenoceptor subtype in human myometrium and its expression is up-regulated in pregnancy. J Clin Endocrinol Metab 2005;90:1644-50
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis. Novel therapeutic uses of beta-3 adrenergic receptor agonist derivatives in particular to modulate apoptosis. WO2009019607; 2009
   Google Scholar
• Zhang Q, Paria BC. Importance of uterine cell death, renewal, and their hormonal regulation in hamsters that show progesterone-dependent implantation. Endocrinology 2006;147:2215-27
   PubMed Web of Science ®Google Scholar
• Smith SC, Baker PN. Increased placental apoptosis in intrauterine growth restriction. Am J Obstet Gynecol 1997;177:1395-401
   PubMed Web of Science ®Google Scholar
• Allaire AD, Ballenger KA, Wells SR, Placental apoptosis in preeclampsia. Obstet Gynecol 2000;96:271-6
   PubMed Web of Science ®Google Scholar
• Erel CT, Dane B, Calay Z, Apoptosis in the placenta of pregnancies complicated with IUGR. Int J Gynaecol Obstet 2001;73:229-35
   PubMed Web of Science ®Google Scholar
• lshihara N, Matsuo H, Murakoshi H, Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol 2002;186:158-66
   PubMed Web of Science ®Google Scholar
• Madazli R, Benian A, Ilvan S, Placental apoptosis and adhesion molecules expression in the placenta and the maternal placental bed of pregnancies complicated by fetal growth restriction with and without pre-eclampsia. J Obstet Gynaecol 2006;26:5-10
   PubMedGoogle Scholar
• Callaghan WM, MacDorman MF, Rasmussen SA, The contribution of preterm birth to infant mortality rates in the United States. Pediatrics 2006;118:1566-73
   PubMed Web of Science ®Google Scholar
• Edwards RK. Chorioamnionitis and labor. Obstet Gynecol Clin North Am 2005;32:287-96
   PubMed Web of Science ®Google Scholar
• Charpigny G, Leroy M-J, Breuiller-Fouche M, A functional genomic study to identify differential gene expression in the preterm and term human myometrium. Biol Reprod 2003;68:2289-96
   PubMed Web of Science ®Google Scholar
• Danial NN, Korsmeyer SJ. Cell death: critical control point. Cell 2004;116:205-19
   PubMed Web of Science ®Google Scholar
• Sanofi Synthelabo. Cyclohexyl(alkyl)-propanolamines, preparation method and pharmaceutical compositions containing same. WO2002044139; 2002
   Google Scholar
• Lirussi F, Rakotoniaina Z, Madani S, ADRB3 adrenergic receptor is a key regulator of human myometrial apoptosis and inflammation during chorioamnionitis. Biol Reprod 2008;78:497-05
   PubMed Web of Science ®Google Scholar
• Trebicka J, Hennenberg M, Probsting AS, Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis. Hepatology 2009;50:1924-35
   PubMed Web of Science ®Google Scholar
• Stemmelin J, Cohen C, Terranova JP, Stimulation of the beta3-adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology 2008;33:574-87
   PubMed Web of Science ®Google Scholar
• Overstreet DH, Stemmelin J, Griebel G. Confirmation of antidepressant potential of the selective beta 3 adrenoceptor agonist amibegron in an animal model of depression. Pharmacol Biochem Behav 2008;89:623-6
   PubMed Web of Science ®Google Scholar
• Stemmelin J, Cohen C, Yalcin I, Implication of beta3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress. Behav Brain Res 2010;206:310-12
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrials.gov
   Google Scholar
• Strosberg AD. The beta3-adrenoreceptor. Taylor & Francis, London; 2000. p. 11
   Google Scholar
• de Souza CJ, Burkey BF. Beta(3)-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr Pharm Des 2001;7:1433-49
   PubMed Web of Science ®Google Scholar
• Perrone MG, Bleve L, Santandrea E, The tertiary amine nitrogen atom of piperazine sulfonamides as a novel determinant of potent and selective beta3-adrenoceptor agonists. Chem Med Chem 2009;4:2080-97
   Google Scholar
• Brockunier LL, Candelore MR, Cascieri MA, Human beta3 adrenergic receptor agonists containing cyanoguanidine and nitroethylenediamine moieties. Bioorg Med Chem Lett 2001;11:379-82
   PubMed Web of Science ®Google Scholar
• Dow RL, Paight ES, Schneider SR, Potent and selective, sulfamide-based human beta3-adrenergic receptor agonists. Bioorg Med Chem Lett 2004;14:3235-40
   PubMed Web of Science ®Google Scholar
• Kashaw SK, Rathi L, Mishra P, Development of 3D-QSAR models in cyclic ureidobenzenesulfonamides: human beta3-adrenergic receptor agonist. Bioorg Med Chem Lett 2003;13:2481-4
   PubMed Web of Science ®Google Scholar
• Mizuno K, Sawa M, Harada H, Discovery of 1, 7-cyclized indoles as a new class of potent and highly selective human beta3-adrenergic receptor agonists with high cell permeability. Bioorg Med Chem 2005;13:855-68
   PubMed Web of Science ®Google Scholar
• Mizuno K, Sawa M, Harada H, Tryptamine-based human beta3-adrenergic receptor agonists. Part 1: SAR studies of the 7-position of the indole ring. Bioorg Med Chem Lett 2004;14:5959-62
   PubMed Web of Science ®Google Scholar
• Nakajima Y, Hamashima H, Washizuka K, Discovery of a novel, potent and selective human beta3-adrenergic receptor agonist. Bioorg Med Chem Lett 2005;15:251-4
   PubMedGoogle Scholar
• Tanaka N, Tamai T, Mukaiyama H, Relationship between stereochemistry and the beta3-adrenoceptor agonistic activity of 4-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence. J Med Chem 2003;46:105-12
   PubMed Web of Science ®Google Scholar
• Steffan R, Ashwell MA, Solvibile WR, Novel substituted 4-aminomethylpiperidines as potent and selective human beta3-agonists. Part 1: aryloxypropanolaminomethylpiperidines. Bioorg Med Chem Lett 2002;12:2957-61
   PubMed Web of Science ®Google Scholar
• Popp BD, Hutchinson DS, Evans BA, Stereoselectivity for interactions of agonists and antagonists at mouse, rat and human beta3-adrenoceptors. Eur J Pharm 2004;484:323-31
   PubMed Web of Science ®Google Scholar
• Peleg G, Ghanouni P, Kobilka BK, Singlemolecule spectroscopy of the beta(2) adrenergic receptor: observation of conformational substates in a membrane protein. Proc Natl Acad Sci USA 2001;98:8469-74
   PubMed Web of Science ®Google Scholar
• Salamon Z, Hruby VJ, Tollin G, Binding of agonists, antagonists, and inverse agonists to the human delta-opioid receptor produces distinctly different conformational states distinguishable by plasmon-waveguide resonance spectroscopy. J Pept Res 2002;60:322-8
   PubMedGoogle Scholar
• Beecham Group PLC. Ethanamine derivatives, their preparation and use in pharmaceutical compositions. EP23385; 1981
   Google Scholar
• Baker JG. The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol 2010;160:1048-61
   PubMed Web of Science ®Google Scholar
• Mori A, Miwa T, Sakamoto K, Pharmacological evidence for the presence of functional beta 3-adrenoceptors in rat retinal blood vessels. Naunyn Schmiedebergs Arch Pharmacol 2010;382:119-26
   PubMed Web of Science ®Google Scholar
• American Cyanamid Co. Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles. US5061727; 1991
   Google Scholar
• Microbial Chem Res F and Banyu Pharma Co. Ltd. N-Methylphenylserine alkyl ester derivatives and uses thereof. EP218440; 1987
   Google Scholar
• Bristol-Myers Squibb Co. Thiazole and oxazole-based beta 3-adrenergic receptor agonists. US5321036; 1994
   Google Scholar
• Merck & Co., IncSubstituted phenyl sulfonamides as selective beta3-agonists for the treatment of diabetes and obesityEP611003; 1994
   Google Scholar
• Yamamoto H, Takakura S, Yamamoto T, FR149175, a beta3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus. Jpn J Pharmacol 1997;74:109-12
   PubMedGoogle Scholar
• Harada H, Hirokawa Y, Suzuki K, Novel and potent human and rat beta3-adrenergic receptor agonists containing substituted 3-indolylalkylamines. Bioorg Med Chem Lett 2003;13:1301-5
   PubMed Web of Science ®Google Scholar
• Weyer C, deSouza CJ. Development of beta3-adrenoceptor agonists as antiobesity and antidiabetes drugs in humans: current status and future prospects. Drug Dev Res 2000;51:80-93
   Web of Science ®Google Scholar
• Strosberg AD. The beta3-adrenoreceptor. Taylor & Francis, London; 2000. p. 58
   Google Scholar
• Strosberg AD. The beta3-adrenoreceptor. Taylor & Francis, London; 2000. p. 66
   Google Scholar
• Strosberg AD. The beta3-adrenoreceptor. Taylor & Francis, London; 2000. p. 65
   Google Scholar
• Hatakeyama Y, Sakata Y, Takakura S, Acute and chronic effects of FR-149175, a beta3-adrenergic receptor agonist, on energy expenditure in Zucker fatty rats. Am J Physiol Regul Integr Comp Physiol 2004;287:R336-41
   Web of Science ®Google Scholar
• Morita T, Iizuka H, Iwata T, Function and distribution of beta3-adrenoceptors in rat, rabbit and human urinary bladder and external urethral sphincter. Smooth Muscle Res 2000;36:21-32
   PubMedGoogle Scholar
• Yanagisawa T, Sato T, Yamada H, Selectivity and potency of agonists for the three subtypes of cloned human beta-adrenoceptors expressed in Chinese hamster ovary cells. Tohoku J Exp Med 2000;192:181-93
   PubMed Web of Science ®Google Scholar
• Hieble JP. Recent advances in identification and characterization of beta-adrenoceptor agonists and antagonists. Curr Top Med Chem 2007;7:207-16
   PubMed Web of Science ®Google Scholar
• Strosberg AD. The beta3-adrenoreceptor. Taylor & Francis, London; 2000. p. 59
   Google Scholar
• Mathvink RJ, Tolman JS, Chitty D, Potent, selective 3-pyridylethanolamine beta3-adrenergic receptor agonists possessing a thiazole benzenesulfonamide pharmacophore. Bioorg Med Chem Lett 2000;10:1971-3
   PubMed Web of Science ®Google Scholar
• Ok HO, Reigle LB, Candelore MR, Substituted oxazole benzenesulfonamides as potent human beta3-adrenergic receptor agonists. Bioorg Med Chem Lett 2000;10:1531-4
   PubMed Web of Science ®Google Scholar
• Hu B, Ellingboe J, Han S, (4-Piperidin-1-yl)phenyl amides: potent and selective human beta3-agonists. J Med Chem 2001;44:1456-66
   PubMed Web of Science ®Google Scholar
• Hu B, Ellingboe J, Gunawan I, 2,4-Thiazolidinediones as potent and selective human beta3-agonists. Bioorg Med Chem Lett 2001;11:757-60
   PubMed Web of Science ®Google Scholar
• Ashwell MA, Solvibile WR, Han S, 4-Aminopiperidine ureas as potent selective agonists of the human beta3-adrenergic receptor. Bioorg Med Chem Lett 2001;11:3123-7
   PubMed Web of Science ®Google Scholar
• Sawa M, Harada H. Recent developments in the design of orally bioavailable beta3-adrenergic receptor agonists. Curr Med Chem 2006;13:25-37
   PubMed Web of Science ®Google Scholar
• Harada H, Hirokawa Y, Suzuki K, Discovery of a novel and potent human and rat beta 3-adrenergic receptor agonist, [3-[(2R)-[[(2R)-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yloxy]acetic acid. Chem Parm Bull 2005;53:184-98
   PubMed Web of Science ®Google Scholar
• Arch JRS, Kaumannl AJ, Molenaarl P, Studies on a novel selective beta3-adrenoceptor agonist in human right atrial appendage and human white adipocytes. Br J Pharmacol 1999;126:100P
   Web of Science ®Google Scholar
• Merck & Co., Inc. Hydroxymethyl pyrrolidines as beta 3-adrenergic receptor agonists. WO2009124167; 2009
   Google Scholar
• Strosberg AD. The beta3-adrenoreceptor. Taylor & Francis, London; 2000. p. 66
   Google Scholar
• Hicks A, McCafferty GP, Riedel E, GW427353 (Solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. JPET 2007;323:202-9
   PubMed Web of Science ®Google Scholar
• King FD. Progress in medicinal chemistry. Volume 41. Oxford AW; 2003. p. 188
   Google Scholar
• van Baak MA, Hul GBJ, Toubro S, Acute effect of L-796568, a novel beta3-adrenergic receptor agonist, on energy expenditure in obese men. Clin Pharmacol Ther 2002;71:272-9
   PubMed Web of Science ®Google Scholar
• Kissei Pharmaceutical. Phenoxyacetic acid derivatives and medicinal compositions containing the same. WO2000002846; 2000
   Google Scholar
• Kissei Pharmaceutical. Medicine for prevention or treatment of frequent urination or urinary incontinence. WO2005089742; 2005
   Google Scholar
• Candelore MR, Deng L, Tota L, Potent and selective human beta(3)-adrenergic receptor antagonists. JPET 1999;290:649-55
   PubMed Web of Science ®Google Scholar

• American Home Prod. Transcriptional regulation of the human beta 3-adrenergic receptor gene. WO20000044901; 2000
   Google Scholar
• American Home Prod. Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists. US2002068751; 2002
   Google Scholar
• American Home Prod. 2-Substituted thiazolidinones as beta-3 adrenergic receptor agonists. WO2002006281; 2002
   Google Scholar
• American Home Prod. N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists. WO2002006274; 2002
   Google Scholar
• American Home Prod. Azolidines as beta-3 adrenergic receptor agonists. WO2002006258; 2002
   Google Scholar
• American Home Prod. Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine beta-3 adrenergic receptor agonists. WO2002006255; 2002
   Google Scholar
• American Home Prod. Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists. WO2002006250; 2002
   Google Scholar
• American Home Prod. Heterocyclic beta-3 adrenergic receptor agonists. WO2002006235; 2002
   Google Scholar
• American Home Prod. Cyclic amine phenyl beta-3 adrenergic receptor agonists. WO2002006232; 2002
   Google Scholar
• American Cyanamid Co. Treatment of glaucoma and ocular hypertension with beta 3-adrenergic agonists. US5578638; 2002
   Google Scholar
• American Cyanamid Co. Beta 3-adrenergic agents and their use in pharmaceutical compositions. US5482971; 1996
   Google Scholar
• American Cyanamid Co. Beta 3-adrenergic agents benzodioxole dicarboxylates and their use in pharmaceutical compositions. US5480908; 1996
   Google Scholar
• American Cyanamid Co. Aminocycloalkanobenzodioxoles as beta-3 selective adrenergic agents. EP608568; 1996
   Google Scholar
• Asahi Kasei Pharma Corp. Indazole compound. WO2010041568; 2010
   Google Scholar
• Asahi Kasei Pharma Corp. Indazole compound. WO2010041569; 2010
   Google Scholar
• Astellas Pharma, Inc. Aminoalcohol derivatives. WO20051109; 2005
   Google Scholar
• Astellas Pharma, Inc. Aminoalcohol derivatives. AU2006202092; 2006
   Google Scholar
• Bayer AG. 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists. WO2002085891; 2002
   Google Scholar
• Bayer AG. Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists. WO2002048134; 2002
   Google Scholar
• Beth Israel Hospital. Transgenic animals deficient in endogenous beta 3-adrenergic receptor and uses thereof. WO9742309; 1997
   Google Scholar
• Boehringer Ingelheim Int. Beta-3-agonist use for treating kidney and bladder troubles of a patient with spinal cord damages. WO2007036543; 2007
   Google Scholar
• Bristol-Myers Squibb Co. Thiazole and oxazole-based beta 3 adrenergic receptor agonists. US5321036; 1994
   Google Scholar
• Bristol-Myers Squibb Co. Catecholamine surrogates useful as beta 3 agonists. EP659737; 1995
   Google Scholar
• Bristol-Myers Squibb Co. Sulfonic, phosphonic or phosphinic acid beta 3 agonist derivatives. US5491134; 1996
   Google Scholar
• Bristol-Myers Squibb Co. Benzo 1,3-dioxole derivatives. US5488064; 1996
   Google Scholar
• Bristol-Myers Squibb Co. Aryloxypropanolamine beta 3 adrenergic agonists. EP714883; 1996
   Google Scholar
• Bristol-Myers Squibb Co. Catecholamine surrogates useful as beta 3 agonists. WO9737646; 1997
   Google Scholar
• Bristol-Myers Squibb Co. Catecholamine surrogates useful as beta 3 agonists. US5770615 (1998)
   Google Scholar
• Bristol-Myers Squibb Co. Aminoethylphenoxyacetic acid derivatives and drugs for pain remission and calculi removal promotion in urinary lithiasis. WO9905090; 2010
   Google Scholar
• Bristol-Myers Squibb Co. 2-Hydroxy-3-(4-hydroxy-3-sulfonamidophenyl)-propylamines useful as beta 3 adrenergic agonists. US2002026065; 2002
   Google Scholar
• Centre Nat Rech Scient. Method for producing adipocytes from non-differentiated fibroblasts and use of resulting adipocytes. WO2000037607; 2002
   Google Scholar
• Centre Nat Rech Scient. Nucleotidic sequences coding for the murine adrenergic beta 3 receiver and applications thereof. WO9212246; 1992
   Google Scholar
• Cedars Sinai Medical Center. Method for reducing the likelihood of the occurrence of cardiac arrhythmias. US2006019954; 2006
   Google Scholar
• Chen Jian. Synthesis and uses of synephrine derivatives. US2005250944; 2005
   Google Scholar
• Kadowaki T, Tobe K, Suzuki R. Compositions and methods for the amelioration of leptin resistance. US2004242485; 2004
   Google Scholar
• Dainippon Pharmaceutical Co. New 2-akylamino-1-phenylethanol derivative. JP8165276; 1996
   Google Scholar
• Dainippon Pharmaceutical Co. 2-(2-(Indol-3-ly)ethylamino)-1-phenylethanol derivative. JP6345731; 1994
   Google Scholar
• Dainippon Pharmaceutical Co. Indole derivative. WO9616938; 1996
   Google Scholar
• Dainippon Pharmaceutical Co. Benzothiophene derivative. JP8157470; 1996
   Google Scholar
• Dainippon Pharmaceutical Co. 3,7-Disubstituted indole derivatives and medicinal compositions containing the same. WO2000044721; 2002
   Google Scholar
• Dainippon Pharmaceutical Co. Heteroarylsulfonanilide derivative and medicinal composition containing the same. WO2004089936; 2004
   Google Scholar
• Dainippon Pharmaceutical Co. Indole compound and pharmaceutical composition containing the same. WO2006078006; 2006
   Google Scholar
• Dainippon Pharmaceutical Co. Method for synthesizing indoles and synthetic intermediate. JP2006169113; 2006
   Google Scholar
• Dainippon Pharmaceutical Co. Sulfonyloxyindole derivative and medicinal composition containing the same. JP2006111553; 2006
   Google Scholar
• Dainippon Pharmaceutical Co. Novel useful therapeutic agent for lower urinary tract symptom. WO2010053068; 2010
   Google Scholar
• Eli Lilly & Co. Selective beta 3 adrenergic agonists. WO9809625; 1998
   Google Scholar
• Eli Lilly & Co. Selective beta 3 adrenergic agonists. WO9929672; 1999
   Google Scholar
• Eli Lilly & Co. Selective beta 3 adrenergic agonists. EP921120; 1999
   Google Scholar
• Eli Lilly & Co. Crystalline salts of 2-(4-{2-[2-hydroxy-3-(2-thiophen-2-yl-phenoxy)-propylamino]-2-methyl-propyl}-phenoxy)-nicotinonitrile. WO2002094820; 2002
   Google Scholar
• Eli Lilly & Co. 3-Substituted oxindole beta 3 agonists. WO2002038543; 2002
   Google Scholar
• Eli Lilly & Co. 3-Substituted oxindole beta 3 agonists. WO2002038544; 2002
   Google Scholar
• Eli Lilly & Co. Beta 3 adrenergic agonists. WO20020124; 2002
   Google Scholar
• Eli Lilly & Co. 3-Substituted oxindole beta 3 agonists. WO2003044016; 2003
   Google Scholar
• Eli Lilly & Co. Beta 3 adrenergic agonists. WO2003016307; 2003
   Google Scholar
• Eli Lilly & Co. Beta 3 adrenergic agonists. WO2003044017; 2003
   Google Scholar
• Eli Lilly & Co. 3-Substituted oxindole beta 3 agonists. WO2003016276; 2003
   Google Scholar
• Fancl Corp. Oligosaccharide-esterified substance effective for obesity and diabetes. JP200616018; 2006
   Google Scholar
• Fancl Corp. Lysophosphatidyl choline effective for obesity, diabetes, etc. JP200616018; 2006
   Google Scholar
• Fujisawa Pharmaceutical Co. New pharmaceutical use of beta 3-adrenalin agonist. JP6293664; 1994
   Google Scholar
• Fujisawa Pharmaceutical Co. New pharmaceutical use of beta 3-adrenalin agonist. JP7228543; 1995
   Google Scholar
• Fujisawa Pharmaceutical Co. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists. WO2000012462; 2000
   Google Scholar
• Fujisawa Pharmaceutical Co. Aminoalcohol derivatives. WO2002094770; 2002
   Google Scholar
• Fujisawa Pharmaceutical Co. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists. WO2003076397; 2003
   Google Scholar
• Fujisawa Pharmaceutical Co. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists. WO2004045610; 2004
   Google Scholar
• Fujisawa Pharmaceutical Co. Aminoalcohol derivatives. US2004106653; 2004
   Google Scholar
• Fujisawa Pharmaceutical Co. Aminoalcohol derivatives. WO2004002939; 2004
   Google Scholar
• Fujisawa Pharmaceutical Co., Astellas Pharma, Inc. Aminoalcohol derivatives. WO2005061433; 2005
   Google Scholar
• Fujisawa Pharmaceutical Co. Astellas Pharma Inc. Aminoalcohol derivatives. US2005137236; 2005
   Google Scholar
• Genaissance Pharmaceuticals. Haplotypes of the adrb3 gene. WO2002008425; 2002
   Google Scholar
• Glaxo Group Ltd. Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists. WO9533724; 1995
   Google Scholar
• Glaxo Group Ltd. Arylethanolamine derivatives and their use as agonists of atypical beta-adrenoceptors. WO9721666; 1997
   Google Scholar
• Glaxo Group Ltd. Naphthalenesulphonic or carboxylic acids and their use as atypical beta-adrenoceptor agonists. WO9843953; 1998
   Google Scholar
• Glaxo Wellcome, Inc. Arylethanolamine derivatives and their use as agonists of atypical beta-adrenoceptors. US6048872; 1998
   Google Scholar
• Glaxo Wellcome, Inc. Therapeutic biaryl derivatives. WO9965877; 1999
   Google Scholar
• Glaxo Group Ltd. Beta-3 adrenoceptor agonists. WO0142217; 2001
   Google Scholar
• Glaxo Group Ltd. Chemical compounds. WO02060885; 2002
   Google Scholar
• Glaxo Group Ltd. Method for producing arylethanoldiamine useful as agonist of beta-adrenoceptor. JP2009137946; 2009
   Google Scholar
• Glenmark Pharmaceuticals Ltd. Novel benzopyran compounds and process for their preparation and use. WO2003014113; 2003
   Google Scholar
• Imperial Chemical Industries Plc.; Zeneca Ltd. 2-Hydroxy-2-phenylethylamine derivatives as beta-3-adrenoceptor agonists. EP516350; 1992
   Google Scholar
• Kaneka Corp. Human beta 3-adrenalin receptor agonist agent. WO2006213657; 2006
   Google Scholar
• Kaken Pharmaceut Co. Ltd. Phenylethanolamine derivative. JP7112958; 2000
   Google Scholar
• Kissei Pharmaceutical. Preventive/remedy for frequent urination and urinary incontinence. WO9807445; 1998
   Google Scholar
• Kissei Pharmaceutical. 2-Methylpropionic acid derivatives and medicinal compositions containing the same. WO9952856; 1999
   Google Scholar
• Kissei Pharmaceutical. Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same. WO9931045; 1999
   Google Scholar
• Kissei Pharmaceutical. Aminoethylphenoxyacetic acid derivatives and drugs for pain remission and calculi removal promotion in urinary lithiasis. WO9905090; 1999
   Google Scholar
• Kissei Pharmaceutical. Crystal polymorphism of aminoethylphenoxyacetic acid derivative dihydrate. JP2000212137; 2000
   Google Scholar
• Kissei Pharmaceutical. Crystal polymorphism of aminoethylphenoxyacetic acid derivative dihydrate. JP2000212138; 2000
   Google Scholar
• Kissei Pharmaceutical. Crystal polymorphism of aminoethylphenoxyacetic acid derivative. JP2000212139; 2000
   Google Scholar
• Kissei Pharmaceutical. Crystal polymorphism of aminoethylphenoxyacetic acid derivative. WO2000043350; 2000
   Google Scholar
• Kissei Pharmaceutical. Phenoxyacetic acid derivatives and medicinal compositions containing the same. WO2000002846; 2000
   Google Scholar
• Kissei Pharmaceutical. Amino alcohol derivative, medicinal composition containing the same, and uses of these. WO2004108674; 2004
   Google Scholar
• Kissei Pharmaceutical. Amino alcohol derivatives, pharmaceutical compositions containing the same, and use of both. WO2004106290; 2004
   Google Scholar
• Kissei Pharmaceutical. Amino alcohol derivative, medicinal composition containing the same, and uses of these. WO2004106283; 2004
   Google Scholar
• Kissei Pharmaceutical. Amino alcohol derivative, medicinal composition containing the same, and use of these. WO2005040093; 2005
   Google Scholar
• Kissei Pharmaceutical. Method for producing aminoalcohol derivative having biphenyl group. WO2006123672; 2006
   Google Scholar
• Kissei Pharmaceutical. Pharmaceutical composition for prevention or treatment of neurogenic pain. WO2007061114; 2007
   Google Scholar
• Kissei Pharmaceutical. Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid. WO2007026630; 2007
   Google Scholar
• L'oreal. Use of alverine or one of its salts. WO2002080877; 2002
   Google Scholar
• Malak JCEG. Chemical compounds derived from octopamine and their uses as beta 3-adrenergic agonists. WO2002081424; 2002
   Google Scholar
• Medicinova, Inc. Method of treatment or prophylaxis of depression. WO2008024787; 2008
   Google Scholar
• Merck & Co., Inc. Substituted phenyl sulfonamides as selective beta 3 agonists for the treatment of diabetes and obesity. EP611003; 1994
   Google Scholar
• Merck & Co., Inc. Substituted sulfonamides as selective beta 3 agonists for the treatment of diabetes and obesity. US5561142; 1996
   Google Scholar
• Merck & Co., Inc. Substituted sulfonamides as selective beta 3 agonists for the treatment of diabetes and obesity. US5541197; 1996
   Google Scholar
• Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective beta 3 agonists for the treatment of diabetes and obesity. WO9746556; 1997
   Google Scholar
• Merck & Co., Inc. Selective B3 agonists for the treatment of diabetes and obesity. GB2305665; 1997
   Google Scholar
• Merck & Co., Inc. Thiazole benzenesulfonamides as beta 3 agonists for the treatment of diabetes and obesity. WO9832753; 1998
   Google Scholar
• Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity. WO9818481; 1998
   Google Scholar
• Merck & Co., Inc. Substituted sulfonamides as selective beta -3 agonists for the treatment of diabetes and obesity. US5705515; 1998
   Google Scholar
• Merck & Co., Inc. Fused piperidine substituted arylsulfonamides as beta 3-agonists. WO9944609; 1999
   Google Scholar
• Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence. WO2007044296; 2007
   Google Scholar
• Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms. WO2008121268; 2008
   Google Scholar
• Merck & Co. Inc. Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists. WO2009123870; 2009
   Google Scholar
• Merck & Co. Inc. Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists. WO2009124166; 2009
   Google Scholar
• Merck & Co. Inc. Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists. WO2009124167; 2009
   Google Scholar
• Metabolic Pharm Ltd. Product and method for control of obesity. WO2002018436; 2002
   Google Scholar
• Pfeizer, Inc. beta3-adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia. CA2158910; 1996
   Google Scholar
• Pfeizer, Inc. Heterocyclic beta-adrenergic agonists. EP8021060; 1997
   Google Scholar
• Pfeizer, Inc. Heterocyclic beta-adrenergic agonists. US5843972; 1998
   Google Scholar
• Pfeizer, Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof. EP1236723; 2002
   Google Scholar
• Pfeizer Products, Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists. WO2002032897; 2002
   Google Scholar
• Pfeizer, Inc. Combinations of beta 3 agonists and growth hormone secretagogues. US6657063; 2003
   Google Scholar
• Pfeizer Products, Inc. Crystal forms of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol. WO2003072573; 2003
   Google Scholar
• Pfeizer Products, Inc. Crystal forms of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol. WO2003072573; 2003
   Google Scholar
• Pfeizer Products, Inc. Salt of a pyridyl ethanolamine derivative and its use as a beta-3-adrenergic receptor agonist. WO2003072571; 2003
   Google Scholar
• Pfeizer, Inc. Beta 3 adrenergic receptor agonist crystal forms, processes for the production thereof, and uses thereof. US2003166686; 2003
   Google Scholar
• Ricom Corp. Human beta3-adrenergic receptor ligand, and food or pharmaceutical product containing the same. WO2009151094; 2009
   Google Scholar
• Sanofi SA; Midy SPA. Phenylethanol aminotetralines, process for their preparation and pharmaceutical compositions containing them. EP0211721; 1987
   Google Scholar
• Sanofi SA; Midy SPA. Process for the preparation of phenylethanolaminotetralines. EP0303545; 1989
   Google Scholar
• Sanofi SA; Midy SPA. Phenylethanolaminomethyltetralins, procedure for their preparation and pharmaceutical compositions containing same. EP0436435; 1991
   Google Scholar
• Sanofi ELF; Midy SPA. Phenylethanolamino- and phenylethanolaminomethyltetralines, process for their preparation, intermediates of this process and pharmaceutical compositions containing them. EP0500443; 1992
   Google Scholar
• Sanofi ELF; Midy SPA. (7S)-7-(2(3-chlorophenyl)-2-hydroxyethylamino-5,6,7,8-tetrahydro-naphthalen-2-yloxy acetic acid, their pharmaceutically acceptable salts with a beta-3-adrenergic agonist activity and pharmaceutical compositions containing them. EP0627407; 1994
   Google Scholar
• Sanofi SA; Midy SPA. (7S)-7-(1R)-2-(3-chlorophenyl)-2-hydroxyethylamino-5,6,7,8-tetrahydronaphtalen-2-yloxy acetic acid, their pharmaceutically acceptable salts with a beta-3-adrenergic agonist activity and pharmaceutical compositions containing them. EP0626367; 1994
   Google Scholar
• Sanofi SA. Use of agonists of adrenergic beta-3 receptors for preparing wound-healing medicines. WO9831357; 1998
   Google Scholar
• Sanofi SA. Use of central cannabinoid receptor antagonists for regulating appetence. WO9832441; 1998
   Google Scholar
• Sanofi SA. Phenoxypropanolamines having beta 3-adrenergic antagonist activity. WO9803485; 1998
   Google Scholar
• Sanofi Synthelabo. Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same. WO9965895; 1999
   Google Scholar
• Sanofi Synthelabo. Heteroaryloxy propanolamines, preparation method and pharmaceutical compositions containing same. WO0117989; 2001
   Google Scholar
• Sanofi Synthelabo. Phenoxypropanolamines, method for producing them and pharmaceutical compositions containing them. WO2001043744; 2001
   Google Scholar
• Sanofi Synthelabo. Phenoxypropanolamines, preparation and therapeutic use thereof. WO2001044227; 2001
   Google Scholar
• Sanofi Synthelabo. Propanolaminotetralines, preparation thereof and compositions containing same. WO2001094307; 2001
   Google Scholar
• Sanofi Synthelabo. Cyclohexyl(alkyl)-propanolamines, preparation method and pharmaceutical compositions containing same. WO2002044139; 2002
   Google Scholar
• Sanofi Synthelabo. Propanolaminomethyltetralines, their preparation and pharmaceutical composition comprising same. FR2833010; 2003
   Google Scholar
• Sanofi Synthelabo. Propanolaminomethyltetralines, their preparation and pharmaceutical composition comprising same. WO2003048117; 2003
   Google Scholar
• Sanofi Synthelabo. Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof. WO2003099772; 2003
   Google Scholar
• Sanofi Synthelabo. Oxophenyl-cyclohexyl-propanolamine derivatives, production and use thereof in therapeutics. WO2003099819; 2003
   Google Scholar
• Sanofi Aventis. Novel therapeutic uses of beta-3 adrenergic receptor agonist derivatives in particular to modulate apoptosis. WO2009019607; 2009
   Google Scholar
• Sanofi Aventis. Beta adrenergic receptor ligand derivatives for modulating apoptosis. EP2011490; 2010
   Google Scholar
• Smithkline Beecham PLC. Arylethanolamine derivatives and their use as beta-3-adrenoceptor agonists. WO9310074; 1993
   Google Scholar
• Smithkline Beecham PLC. Arylethanolamine derivatives and their use in the treatment of obesity and hyperglycaemia. WO9424090; 1994
   Google Scholar
• Smithkline Beecham PLC. Aryloxy andarycthio propanolamine derivatives useful as beta3-adrenoreceptor agonists and antagons of the beta1- and beta2-adrenoreceptors and pharmaceutical composition thereof. WO9604234; 1996
   Google Scholar
• Smithkline Beecham PLC. Aryloxy and arylthiopropanolamine derivatives useful as beta 3-adrenoreceptor agonists and antagonists of the beta 1- and beta 2-adrenoreceptors and pharmaceutical composition thereof. WO9604233; 1996
   Google Scholar
• Sumitomo Pharma. Cyclic amine and medicinal composition containing the same. WO2003106423; 2003
   Google Scholar
• Sumitomo Pharma. Indole, indazole, and benzazole derivative. WO2003106418; 2003
   Google Scholar
• Sawai Seiyaku Kk. Phenoxyacetic acid derivative. JP11035534; 1999
   Google Scholar
• Tokyo Tanabe Co. Ltd. Tetrahydrobenzothiophene derivative. JP10152488; 1998
   Google Scholar
• Toyo Shinyaku Co. Ltd. Enhancer of expression of beta 3-adrenergic receptor. WO2010010786; 2010
   Google Scholar
• Univ Wayne State. Beta 3-adrenergic receptor protein and DNA encoding same. WO9402590; 1994
   Google Scholar
• Univ Maryland. Genetic markers which identify individuals who improve their diabetes status with exercise. WO2000031297; 2000
   Google Scholar
• Univ Johns Hopkins Med. Susceptibility gene for obesity and type ii diabetes mellitus. JP2006169113; 2006
   Google Scholar
• Vetigen. Canine beta 2- and beta 3-adrenergic receptors and use thereof. WO9735973; 1997
   Google Scholar
• Vetigen. Nucleotide sequences coding for the bovine beta 3-adrenergic receptor, and applications thereof. WO9424162; 1996
   Google Scholar
• Virbac SA. Aryloxypropanolamine derivatives, method of preparation and applications thereof. WO9820005; 1998
   Google Scholar
• 4SC AG. Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments. WO2008090140; 2008
   Google Scholar
• Univ. degli Studi di Bari. Beta-3 receptor ligands and their use in therapy. WO2008015558; 2008
   Google Scholar
• Univ. Reading. Beta adrenergic receptor pharmacophore. WO2007045893; 2007
   Google Scholar
• Univ North Carolina. Methods and materials for determining pain sensitivity and predicting and treating related disorders. WO2007001324; 2007
   Google Scholar
• Yamanouchi Pharmaceut Co. Ltd. New guanidine derivative or salt thereof. JP10158233; 1998
   Google Scholar